Literature DB >> 28138587

Multiple localized metachronous recurrences in a patient of colon cancer and therapeutic controversies in stage II colon cancer.

Vijai Simha1, Rakesh Kapoor1, Saniya Sharma1.   

Abstract

Recurrences of colon cancer occurs in 30-40% of the patients after successful initial therapy and most commonly occur at distant sites like liver, lungs and lymph nodes. Here we present a patient who presented with localized metachronous recurrences of colonic cancer over a span of 20 years; each time presenting in stage II and was successfully salvaged with surgery followed by adjuvant chemotherapy. Recurrences were detected on screening colonoscopy at each instance. We also discuss the role of adjuvant chemotherapy in stage II colon cancer, current indications of chemotherapy and the role of gene assays. The independent survival benefit conferred by screening treated patients with colon cancer is also highlighted.

Entities:  

Keywords:  Colon cancer; metachronous; recurrent; screening

Year:  2016        PMID: 28138587      PMCID: PMC5244597          DOI: 10.21037/tgh.2016.03.05

Source DB:  PubMed          Journal:  Transl Gastroenterol Hepatol        ISSN: 2415-1289


  22 in total

1.  Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04)

Authors:  E Mamounas; S Wieand; N Wolmark; H D Bear; J N Atkins; K Song; J Jones; H Rockette
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

2.  Microsatellite instability and adjuvant fluorouracil chemotherapy: a mismatch?

Authors:  Kimmie Ng; Deborah Schrag
Journal:  J Clin Oncol       Date:  2010-05-24       Impact factor: 44.544

3.  High-risk groups of patients with Stage II colon carcinoma.

Authors:  S Merkel; A Wein; K Günther; T Papadopoulos; W Hohenberger; P Hermanek
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

4.  Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial.

Authors:  Aimery de Gramont; Eric Van Cutsem; Hans-Joachim Schmoll; Josep Tabernero; Stephen Clarke; Malcolm J Moore; David Cunningham; Thomas H Cartwright; J Randolph Hecht; Fernando Rivera; Seock-Ah Im; György Bodoky; Ramon Salazar; Frédérique Maindrault-Goebel; Einat Shacham-Shmueli; Emilio Bajetta; Martina Makrutzki; Aijing Shang; Thierry André; Paulo M Hoff
Journal:  Lancet Oncol       Date:  2012-11-16       Impact factor: 41.316

5.  Number of nodes examined and staging accuracy in colorectal carcinoma.

Authors:  J H Wong; R Severino; M B Honnebier; P Tom; T S Namiki
Journal:  J Clin Oncol       Date:  1999-09       Impact factor: 44.544

6.  Long-term survival results of surgery alone versus surgery plus 5-fluorouracil and leucovorin for stage II and stage III colon cancer: pooled analysis of NSABP C-01 through C-05. A baseline from which to compare modern adjuvant trials.

Authors:  Neal W Wilkinson; Greg Yothers; Samia Lopa; Joseph P Costantino; Nicholas J Petrelli; Norman Wolmark
Journal:  Ann Surg Oncol       Date:  2010-04       Impact factor: 5.344

7.  Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.

Authors:  C G Moertel; T R Fleming; J S Macdonald; D G Haller; J A Laurie; C M Tangen; J S Ungerleider; W A Emerson; D C Tormey; J H Glick
Journal:  J Clin Oncol       Date:  1995-12       Impact factor: 44.544

8.  Allelic loss of chromosome 18q and prognosis in colorectal cancer.

Authors:  J Jen; H Kim; S Piantadosi; Z F Liu; R C Levitt; P Sistonen; K W Kinzler; B Vogelstein; S R Hamilton
Journal:  N Engl J Med       Date:  1994-07-28       Impact factor: 91.245

9.  Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.

Authors:  Amy J French; Daniel J Sargent; Lawrence J Burgart; Nathan R Foster; Brian F Kabat; Richard Goldberg; Lois Shepherd; Harold E Windschitl; Stephen N Thibodeau
Journal:  Clin Cancer Res       Date:  2008-06-01       Impact factor: 12.531

10.  Adjuvant chemotherapy for stage II right-sided and left-sided colon cancer: analysis of SEER-medicare data.

Authors:  Jennifer M Weiss; Jessica Schumacher; Glenn O Allen; Heather Neuman; Erin O'Connor Lange; Noelle K Loconte; Caprice C Greenberg; Maureen A Smith
Journal:  Ann Surg Oncol       Date:  2014-03-19       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.